Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of 131I-TLX101 with standard chemoradiation in newly diagnosed glioblastoma
NL-OMON53391Phase 1Not yet recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Mar 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 4-iodophenylalanine I-131 in glioblastoma (GBM), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Safety and tolerability of 131I-TLX101 plus standard of care and Dose-limiting toxicities. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
4-iodophenylalanine I-131
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON53391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53391.